From the publishers of JADPRO

DLBCL Resource Center


Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

Data from a multicenter, prospective study of elderly patients with newly diagnosed DLBCL who underwent baseline comprehensive geriatric assessment demonstrated that an impairment of instrumental activities of daily living was independently associated with grade 3/4 leukopenia (OR 0.63; 95% CI, 0.43-0.92; P = 0.017) and anemia (OR 0.67; 95% CI, 0.50-0.90; P = 0.008). In addition, presence of a comorbidity was associated with grade 3/4 nonhematological toxicity (OR 2.17; 95% CI, 1.37-3.43; P = 0.001).

Scientific Reports
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management


Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study


Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma


Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial